In Situ STING-Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti-PD-1-Resistant Tumors.
Sign Up to like & getrecommendations! Published in 2023 at "Advanced materials"
DOI: 10.1002/adma.202300171
Abstract: Immunotherapies comprising programmed cell death protein 1/PD ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors are effective cancer treatments. However, the low response rate and immunoresistance resulting from alternative immune checkpoint upregulation and inefficient immune stimulation by… read more here.
Keywords: situ sting; cell; activating nanovaccination; sting activating ... See more keywords
Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer research"
DOI: 10.1158/0008-5472.can-18-0734
Abstract: PD-1-based cancer immunotherapy is a successful example of immune checkpoint blockade that provides long-term durable therapeutic effects in patients with cancer across a wide spectrum of cancer types. Accumulating evidence suggests that anti-PD-1 therapy enhances… read more here.
Keywords: anti resistant; cd8 cells; tumor model; exhausted cd8 ... See more keywords
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-2046
Abstract: Abstract Purpose: Intratumoral oncolytic virotherapy may overcome anti–PD(L)-1 resistance by triggering pro-inflammatory remodeling of the tumor microenvironment. This pilot study investigated ONCOS-102 (oncolytic adenovirus expressing GM-CSF) plus anti–programmed cell death protein 1 (PD)-1 therapy in… read more here.
Keywords: advanced melanoma; remodeling tumor; anti resistant; oncos 102 ... See more keywords
For Whom the Bell Tolls? A Toll-Like Receptor 9 Agonist's Journey from Vaccine Adjuvant to Promising Agent in Anti-PD-1-Resistant Melanoma.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-21-1226
Abstract: SUMMARY Developing effective therapies in anti-PD-1-resistant melanoma is a key unmet need. The combination of pembrolizumab with the intralesional TLR9 agonist vidutolimod showed promise in this patient population with correlative analysis suggesting that patients with… read more here.
Keywords: tolls toll; resistant melanoma; bell tolls; anti resistant ... See more keywords
BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco-24-02595
Abstract: PURPOSE Patients with anti–PD-1–resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanoplexed with polyethylenimine that when administered intratumorally has showed in patients with solid tumors potential… read more here.
Keywords: patients anti; clinical trial; 112 plus; phase clinical ... See more keywords
Cetuximab plus dalpiciclib in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.6026
Abstract: 6026 Background: Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is characterized by hyperactivation of the cyclin-dependent kinase 4/6 (CDK4/6) pathway. As immunotherapy has become the first-line treatment for HNSCC, resistance to anti-programmed… read more here.
Keywords: head neck; cell; hpv negative; hnscc ... See more keywords